2008-12-03 21:20:01 -

RBC Capital Markets 2008 Healthcare Conference - Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that David McGirr, SVP and CFO, will present on Wednesday, December 10th at 9:00 A.M. ET at the RBC Capital Markets 2008 Healthcare Conference being held at the Westin New York at Times Square in New York City. The webcast panel format will include

discussion of the company"s business activities, financial outlook and current news.
The live audio webcast of the presentation will be accessible through Cubist"s website at www.cubist.com in the Investor Relations Conference Calendar section. The webcast will be available on Cubist"s website for a period of 30 days after the presentation.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. Cubist has entered into an agreement with AstraZeneca to handle U.S. hospital sales for their established broad spectrum antibiotic, MERREM I.V.® (meropenem for injection). The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials for the prevention of blood loss during cardiothoracic surgery, and pre-clinical programs that address unmet medical needs in Gram-negative infections, CDAD (Clostridium difficile-associated diarrhea), and HCV (Hepatitis C infections). Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist"s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.


Cubist Pharmaceuticals, Inc.

Eileen C. McIntyre, 781-860-8533

Senior Director, Corporate Communications

eileen.mcintyre@cubist.com